Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Retina, Business and Innovation, Health Economics and Policy

Shifting the AMD Burden-Benefit Balance

At a Glance

  • The ALTAIR trial recently provided evidence to support new aflibercept treatment regimen
  • Eight-weekly aflibercept dosing was associated with 96-week efficacy and safety outcomes similar to those of a monthly ranibizumab regime
  • Later intervals varied from 8 to 16 weeks, the interval being adjusted on the basis of individual patient characteristics
  • Treat-and-extend dosing earlier in the first year of aflibercept treatment has resulted in excellent visual outcomes, and reduced burden of treatment for many patients.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Rod McNeil

Rod McNeil is an independent medical journalist.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register